TOP STORIES

• REGULATORY AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support
  December 28, 2016

• BUSINESS 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
  December 27, 2016

• ORGANIZATION Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
  December 26, 2016

• BUSINESS Sumitomo Dainippon to Buy US Hematology Startup Tolero
  December 22, 2016

• BUSINESS Ono Slashes Opdivo Sales Outlook on 50% Price Cut
  December 22, 2016

• REGULATORY Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
  December 21, 2016

• BUSINESS New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
  December 21, 2016

• REGULATORY Four Ministers Map Out Basic Policy for Drug Pricing Revamp
  December 21, 2016

• REGULATORY Basic Policy for Drastic Reform of Drug Pricing System
  December 20, 2016

• BUSINESS Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
  December 20, 2016

• ACADEMIA New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
  December 19, 2016

• BUSINESS Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
  December 16, 2016

• BUSINESS Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
  December 16, 2016

• ORGANIZATION JMA Wants Adjustment Rate as High as 5%: Yokokura
  December 15, 2016

• REGULATORY PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
  December 15, 2016

• REGULATORY MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
  December 14, 2016

• REGULATORY Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
  December 14, 2016

• BUSINESS Aspen Japan Starting on Right Foot on AG Biz: GSK Japan President
  December 13, 2016

• REGULATORY Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
  December 12, 2016

• REGULATORY (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
  December 12, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 162
• 163
• 164
• 165
• 166
• 167
• 168
• 169
• 170
• …
• Next ›
• 最終 »